Nucleic Acid Extraction Instruments and Reagents Global Market Report 2024

The nucliec acid extraction instruments and reagents market size has grown rapidly in recent years. It will grow from $4.22 billion in 2023 to $4.68 billion in 2024 at a compound annual growth rate (CAGR) of 10.9%. The growth observed in the historical period can be attributed to several key factors, including advancements in genomic research, the expansion of clinical diagnostics, the emergence and adoption of next-generation sequencing technologies, a rising prevalence of genetic disorders, and a global focus on infectious disease research. These factors collectively contributed to the growth and development of nucleic acid extraction instruments and reagents.

The nucliec acid extraction instruments and reagents market size is expected to see rapid growth in the next few years. It will grow to $7 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. Anticipated growth in the upcoming period is expected to be driven by rapid advancements in personalized medicine, the expansion of point-of-care testing, heightened emphasis on research pertaining to rare diseases, and notable progress in cancer research. These factors are set to significantly influence the growth trajectory of nucleic acid extraction instruments and reagents. Foreseen trends in this forecast period encompass applications in agricultural biotechnology, noteworthy technological advancements in automation, a burgeoning biotechnology landscape, the utilization of environmental DNA (eDNA) analysis, and the integration of blockchain technology to enhance the security of genomic data. These trends are expected to shape and redefine the landscape of nucleic acid extraction instruments and reagents.

The anticipated surge in the prevalence of chronic diseases is set to drive the growth of the nucleic acid extraction instruments and reagents market. Chronic diseases, characterized by prolonged durations and gradual progression, necessitate advanced medical tools for diagnosis, monitoring, and treatment. Nucleic acid extraction instruments and reagents assume a critical role in this context, particularly in molecular diagnostics and research. These instruments and reagents are indispensable for genetic testing, biomarker analysis, research endeavors, pharmacogenomic testing, and disease monitoring, collectively contributing to an enhanced understanding and management of chronic conditions. As of January 2023, the National Centre for Biotechnology Information reported an expected 99.5% increase in chronic conditions, projecting a rise from 71.522 million in 2020 to 142.66 million by 2050. This substantial increase in chronic diseases underscores the pivotal role played by nucleic acid extraction instruments and reagents in advancing medical research and diagnostics.

The growing demand for personalized medicine is poised to fuel the expansion of the nucleic acid extraction instruments and reagents market. Personalized medicine, aimed at tailoring medical treatments based on individual characteristics, including genetic makeup, relies on specific nucleic acid extraction instruments and customized reagents. These tools enable the isolation and analysis of individual genetic material, facilitating the development of personalized treatment plans tailored to a patient's unique genetic profile. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines by the Personalized Medicine Coalition (PMC). This emphasizes the increasing adoption of personalized medicine and its pivotal role in driving the growth of the nucleic acid extraction instruments and reagents market.

Technological advancements emerge as a prominent trend in the nucleic acid extraction instruments and reagents market, with companies actively integrating new technologies to fortify their market standing. An exemplar in this regard is the November 2021 launch by One BioMed Pte Ltd, a Singapore-based molecular life science company, of the Xceler8(TM) Nucleic Acid Extraction Technology, a cartridge-based platform. Representing a significant milestone in nucleic acid extraction technology, the Xceler8 Platform stands out for its radical simplification of sample preparation, creating a seamless workflow for users involved in nucleic acid extraction, such as DNA or RNA, from biological samples.

Major companies in the nucleic acid extraction instruments and reagents market are directing their focus toward advanced solutions, including extraction-free viral sample preparation, to enhance efficiency and speed in the diagnostic process while ensuring heightened accuracy in detecting viral infections. Extraction-free viral sample preparation involves preparing samples for viral analysis without the need for isolating or extracting genetic material. In March 2021, Promega Corporation, a prominent US-based manufacturer of reagents, assays, and benchtop instruments, launched XpressAmp Direct Amplification Reagents, designed for automation-friendly RNA extraction-free sample preparation. This innovative solution empowers laboratories conducting COVID-19 testing by providing a tool that allows them to bypass the potentially bottlenecked RNA extraction step in the workflow, facilitating a direct transition to polymerase chain reaction (PCR) amplification. The incorporation of such advanced technologies underscores the industry's commitment to optimizing diagnostic workflows and improving overall efficiency in nucleic acid extraction processes.

In January 2023, Qiagen N.V., a prominent biotechnology research company headquartered in Germany, completed the acquisition of Verogen Ltd for an estimated $150 million. This strategic acquisition by Qiagen grants exclusive distribution rights for a specialized MiSeq sequencer variant tailored specifically for forensics applications. Verogen Ltd, based in the Netherlands, specializes in the development of DNA-based biometric human identification products and nucleic acid extraction solutions.

Major companies operating in the nucleic acid extraction instruments and reagents market report are Thermo Fisher Scientific Inc., F Hoffmann-La Roche Ltd., Merck Group, Corning Incorporated, Agilent Technologies Inc., PerkinElmer, Illumina Inc., Beckman Coulter, Bio-Rad Laboratories Inc., Qiagen NV, Eppendorf AG, LGC Biosearch Technologies, Promega Corporation, RBC Bioscience Corp., Takara Bio Inc., Meridian Bioscience, Bioneer Corporation, Macherey-Nagel, New England Biolabs, Miltenyi Biotec, Omega Bio-tek, BioVision Inc., Norgen Biotek Corp., Biosan Laboratories Inc., G-Biosciences, ADS Biotec Inc., BioChain Institute Inc., Lucigen Corporation.

North America was the largest region in the nucleic acid extraction instruments and reagents market in 2023. The regions covered in the nucleic acid extraction instruments and reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nucleic acid extraction instruments and reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

These essential tools and substances come in various types, including instruments, spin columns, beads (including magnetic ones), automated nucleic acid extraction systems, extraction kits and reagents, and consumables. Instruments are devices serving multiple functions, such as measurement, analysis, or experimentation. Extraction methods such as DNA, RNA, or DNA/RNA extraction rely on solution-based or solid-phase-based techniques. These products cater to diverse end users such as academic research institutes, hospitals, diagnostic centers, pharmaceutical and biotechnology industries, and contract research organizations (CROs).

The nucleic acid extraction instruments and reagents market research report is one of a series of new reports that provides nucleic acid extraction instruments and reagents market statistics, including nucleic acid extraction instruments and reagents industry global market size, regional shares, competitors with a nucleic acid extraction instruments and reagents market share, detailed nucleic acid extraction instruments and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid extraction instruments and reagents industry. This nucleic acid extraction instruments and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nucleic acid extraction instruments and reagents market consists of revenues earned by entities by providing nucleic acid extraction instruments and reagents services such as data management and analysis, and laboratory information management systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid extraction instruments and reagents market also includes sales of centrifuges, thermal cyclers, and robotic platforms, which are used in providing nucleic acid extraction instruments and reagents services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.